{"id":"NCT02564263","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)","officialTitle":"A Phase III Randomized Open-Label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects With Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus That Have Progressed After First-Line Standard Therapy (KEYNOTE-181)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-12-01","primaryCompletion":"2018-10-15","completion":"2022-03-14","firstPosted":"2015-09-30","resultsPosted":"2019-11-20","lastUpdate":"2023-03-13"},"enrollment":628,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Esophageal Carcinoma","Esophagogastric Junction Carcinoma"],"interventions":[{"type":"BIOLOGICAL","name":"pembrolizumab","otherNames":["KEYTRUDA速","MK-3475"]},{"type":"DRUG","name":"paclitaxel","otherNames":["TAXOL速"]},{"type":"DRUG","name":"docetaxel","otherNames":["TAXOTERE速"]},{"type":"DRUG","name":"irinotecan","otherNames":["CAMPTOSAR速"]}],"arms":[{"label":"Pembrolizumab","type":"EXPERIMENTAL"},{"label":"Chemotherapy","type":"ACTIVE_COMPARATOR"}],"summary":"In this study, participants with advanced or metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or Siewert type I adenocarcinoma of the esophagogastric junction (EGJ) that had progressed after first-line standard therapy were randomized to receive either pembrolizumab (MK-3475) OR the Investigator's choice of standard chemotherapy with paclitaxel, docetaxel, or irinotecan.\n\nThe primary study hypothesis was that treatment with pembrolizumab would prolong overall survival (OS) as compared to treatment with standard chemotherapy.","primaryOutcome":{"measure":"Overall Survival (OS) in Participants With Squamous Cell Carcinoma (SCC) of the Esophagus","timeFrame":"Through Final Analysis data cutoff date of 15-Oct-2018 (up to approximately 34 months)","effectByArm":[{"arm":"Pembrolizumab","deltaMin":8.2,"sd":null},{"arm":"Chemotherapy","deltaMin":7.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.00894"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":19},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["33026938","34730989"],"seeAlso":["http://merckoncologyclinicaltrials.com/"]},"adverseEventsSummary":{"seriousAny":{"events":127,"n":314},"commonTop":["Fatigue","Decreased appetite","Nausea","Anaemia","Diarrhoea"]}}